Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation
|
|
- Jonathan Clarke
- 5 years ago
- Views:
Transcription
1 2584 OSANAI H et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society Arrhythmia/Electrophysiology Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation Hiroyuki Osanai, MD; Masayoshi Ajioka, MD; Tomohiro Masutomi, MD; Tasuku Kuwayama, MD; Sota Ishihama, MD; Yusuke Sakamato, MD; Naoya Otaka, MD; Teruhiro Sakaguchi, MD; Yosuke Inoue, MD; Takahiro Kanbara, MD; Yoshihito Nakashima, MD; Hiroshi Asano, MD; Kazuyoshi Sakai, MD Background: Chromogenic anti-factor Xa activity (AXA) assay is reported to be the most appropriate method to measure the pharmacodynamics of apixaban, but the distribution of AXA in non-valvular atrial fibrillation (NVAF) patients on apixaban therapy has not been fully elucidated. Methods and Results: Steady-state trough and peak AXA were measured in 124 NVAF patients taking apixaban. In 25 patients, baseline, first peak, and trough AXA were also examined, and were 0.01±0.02 IU/ml, 0.83±0.43 IU/ml, and 0.34±0.17 IU/ml, respectively. First trough AXA was significantly lower than steady-state trough AXA, although it was significantly higher than baseline (P<0.0001). Similarly, first peak AXA was significantly lower than steady-state peak AXA (P<0.0001). In 124 patients, steady-state peak AXA was significantly higher in the 5-mg b.i.d. group than in the 2.5-mg b.i.d. group (2.05±0.73 IU/ml vs. 1.51±0.65 IU/ml, respectively; P<0.001), although there was no significant difference in trough AXA. Other than dose, age and serum creatinine were significantly related to both trough and peak AXA. Conclusions: The distribution of AXA in Japanese NVAF patients on apixaban therapy in daily clinical practice both in the acute and steady-state phase was measured. In patients taking apixaban, measurement of AXA clearly showed the pharmacodynamic profile of this drug. (Circ J 2015; 79: ) Key Words: Anti-factor Xa activity; Apixaban; Atrial fibrillation Apixaban is an oral, direct, and selective factor-xa (FXa) inhibitor approved worldwide for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). 1 4 The usually recommended dosage of apixaban is a 5-mg tablet twice daily (b.i.d.), while a 2.5-mg tablet b.i.d. is recommended for patients with at least 2 of the following conditions: age 80 years, body weight 60 kg, or serum creatinine 1.5 mg/dl. 1 Similar to other non-vitamin K oral anticoagulants (NOAC), biological monitoring and dose adjustment following the results of monitoring are not usually recommended in patients on apixaban due to its proven efficacy and safety. 1,5 8 These findings were obtained in large-scale clinical trials and may be applicable only to patients who met the inclusion criteria for each trial. Thus, the lack of predictable drug level measurement may hinder the management of patients on anticoagulant therapy with NOAC in real clinical practice. That is to say, monitoring anticoagulant activity might be useful in dealing with patients undergoing emergency surgery or with hemorrhage, to determine the optimal dose in individual patients, excluding under or over dosage, and estimating adherence to therapy, especially in cases of unexpected thromboembolic events. 9 One study reported that prothrombin time (PT) measured using specific reagents can predict apixaban-associated anticoagulant activity, although there is significant interpatient variability. 10 In contrast, chromogenic anti-factor Xa activity (AXA) assay was found to be the most appropriate method to measure the pharmacodynamics of apixaban, and the broadly used coagulation assays such as PT or activated partial thromboplastin time (aptt) are not appropriate to effectively estimate plasma drug concentration due to several limitations and a lack of sensitivity. 8,11 13 Editorial p 2539 Therefore, the aims of the present study were to determine the distribution of trough and peak AXA in Japanese NVAF patients receiving apixaban and to assess the impact of AXA on clinical outcome. Received April 28, 2015; revised manuscript received August 25, 2015; accepted September 6, 2015; released online October 6, 2015 Time for primary review: 13 days Division of Cardiology, Tosei General Hospital, Seto, Japan Mailing address: Hiroyuki Osanai, MD, Division of Cardiology, Tosei General Hospital, 160 Nishi Oiwake-cho, Seto , Japan. osanai@tosei.or.jp ISSN doi: /circj.CJ All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 Anti-Factor Xa Activity on Apixaban 2585 Table 1. Patient Characteristics Total (n=124) 5 mg b.i.d. (n=76) 2.5 mg b.i.d. (n=48) P-value Age (years) 77.5± ± ±6.2 <0.01 Male sex 62 (50.0) 43 (56.6) 19 (39.6) 0.07 Body weight (kg) 56.8± ± ±10.0 <0.01 Paroxysmal AF 58 (46.8) 37 (48.7) 21 (43.8) 0.59 Under dose 9 (7.3) 9 (18.8) Serum creatinine (mg/dl) 1.02± ± ±0.43 <0.05 Mean creatinine clearance (ml/min) 51.0± ± ±15.7 <0.01 Mean CHADS2 score 2.1± ± ±1.1 < (8.1) 9 (11.8) 1 (2.1) (25.0) 24 (31.6) 7 (14.6) < (33.1) 24 (31.6) 17 (35.4) (33.9) 19 (25.0) 23 (47.9) <0.01 Congestive heart failure 49 (39.5) 18 (39.9) 31 (64.6) <0.01 Hypertension 84 (67.7) 53 (67.5) 31 (64.6) 0.55 Age 75 years 85 (70.2) 39 (61.1) 46 (95.8) <0.01 Diabetes mellitus 27 (21.8) 16 (20.2) 11 (22.9) 0.81 Baseline stroke/tia/systemic embolism 10 (8.1) 6 (7.9) 4 (8.3) 0.93 Previous anticoagulants None 74 (59.7) 50 (65.8) 24 (50.0) 0.08 Warfarin 41 (33.1) 20 (26.3) 21 (43.8) <0.05 Dabigatran 4 (3.2) 2 (2.6) 2 (4.2) 0.64 Rivaroxaban 5 (4.0) 4 (5.3) 1 (2.1) 0.38 Concurrent antiplatelet drugs Total 29 (23.0) 16 (21.1) 13 (27.1) 0.44 Aspirin 10 (7.9) 5 (6.6) 5 (10.4) 0.44 Clopidogrel 14 (11.1) 8 (10.5) 6 (12.5) 0.74 Cilostazol 2 (1.6) 2 (2.6) 0 (0) 0.26 Aspirin+clopidogrel 3 (2.4) 1 (1.3) 2 (4.2) 0.31 Data given as mean ± SD or n (%). AF, atrial fibrillation; TIA, transient ischemic attack. Methods Study Design and Participants This observational study of Japanese patients with NVAF on apixaban was conducted in routine clinical practice at Tosei General Hospital, Aichi, Japan. From 1 October 2013 to 31 October 2014, 203 patients were started on apixaban and were considered for study entry. Trough and peak AXA after repeated apixaban intake were measured in 124 of these patients in the outpatient clinic; in 25 of these patients, AXA was measured immediately before, 3 h after, and 12 h after the first dose of apixaban in the hospital. The correlations between AXA and routine coagulation markers (PT and aptt) were also examined in these 124 patients after repeated apixaban intake. Patients gave written, informed consent to participate, and this study was conducted in accordance with the ethics policies of Tosei General Hospital. The observation period lasted until 31 January Creatinine clearance was determined using the Cockcroft- Gault formula: men, [(140 age)/(serum creatinine)] (weight/72); women, 0.85 [(140 age)/(serum creatinine)] (weight/72)]. Measuring AXA and Routine Coagulation Markers The HemosIL Liquid Heparin Kit (Instrumentation Laboratory, Lexington, KY, USA) was used for the chromogenic AXA assay. This 1-stage assay is based on the reaction between FXa and a synthetic chromogenic substrate. For Liquid Heparin, 10 μl of plasma were mixed with 100 μl chromogenic substrate Figure 1. Baseline, first peak and trough and steady-state trough and peak anti-factor Xa activity (AXA) in 25 patients. The respective measurements were 0.01±0.02 IU/ml, 0.83±0.43 IU/ml, 0.34±0.17 IU/ml, 0.92±0.52 IU/ml, and 1.61±0.62 IU/ml. First trough AXA was significantly lower than steady-state trough AXA, although it was significantly higher than baseline. Similarly, first peak AXA was significantly lower than steady-state peak AXA.
3 2586 OSANAI H et al. Figure 2. Plot of steady-state trough and peak anti-factor Xa activity (AXA) according to the dosage and consistency with the recommendation. Steady-state peak AXA was significantly higher than trough AXA in (A) the 5-mg b.i.d. group (n=76, P<0.0001), (B) the 2.5-mg b.i.d. group (n=39, P<0.0001); and (C) the under-dosed 2.5-mg b.i.d. group (n=9, P<0.05). and incubated at 37 C. After 75 μl of bovine FXa were added, the chromogenic substrate was hydrolyzed by FXa releasing p-nitroaniline. The quantity of p-nitroaniline released was determined on photometry at 405 nm, and the measurement was performed with the ACL TOP Hemostasis Testing System (Instrumentation Laboratory). 11 The standard HemosIL Heparin Calibrators (Instrumentation Laboratory) were used, and AXA was expressed in heparin international units (IU)/ml. AXA at trough and peak times after repeated apixaban intake was measured >72 h after the start of treatment. The trough time was defined as immediately before the intake of apixaban, and the peak time was defined as 3 h after the intake of apixaban. To ensure measurement at the precise times corresponding to trough concentration, patients took the drug at the hospital after the first blood collection in the morning. Then, blood was collected again 3 h later to measure peak concentration accurately. These measurements were defined as steady-state trough AXA and peak AXA. In contrast, AXA at the beginning of apixaban therapy was measured immediately before, 3 h after, and 12 h after the first intake of apixaban on admission, and was defined as baseline AXA, first peak AXA, and first trough AXA, respectively. PT was measured using HemosIL RecombiPlasTin (Instrumentation Laboratory), and aptt was measured using HemosIL APTT-SP (Instrumentation Laboratory). Outcomes Outcome events included stroke or any other form of embolism affecting a major organ. In the safety evaluation, major and non-major clinically relevant bleeding events were included. A major bleeding event was defined, according to the International Society on Thrombosis and Haemostasis criteria, as clinically overt bleeding accompanied by a decrease in hemoglobin 20 g/l or transfusion 2 units of packed red cells occurring at a critical site or resulting in death. 1,14 A non-major clinically relevant bleeding event was defined as clinically overt bleeding that did not satisfy the criteria for major bleeding but that required medical intervention or resulted in the impairment of daily activities. Statistical Analysis Categorical variables are presented as numbers and percentages. Continuous variables are presented as mean ± SD. To measure the strength of the relationship between 2 variables, Spearman s
4 Anti-Factor Xa Activity on Apixaban 2587 Figure 3. Distribution of steady-state trough and peak anti-factor Xa activity (AXA) according to dosage and consistency with the recommendation. (A) Trough AXA did not differ significantly among the 3 groups (1.00±0.66 IU/ml, 0.84±0.47 IU/ml, and 0.59±0.38 IU/ml, respectively; P=0.146). (B) Peak AXA was significantly higher in the 5-mg b.i.d. group than in the 2.5-mg b.i.d. group (2.05±0.73 IU/ml vs. 1.51±0.65 IU/ml, respectively; P<0.001) and in the under-dosed 2.5-mg b.i.d. group (2.05±0.73 IU/ml vs. 1.23±0.46 IU/ml, respectively; P<0.01). Figure 4. Relationship between steady-state trough and peak anti-factor Xa activity (AXA) and prothrombin time (PT) in the overall patients. Significant and moderate positive correlation was observed between the AXA and PT both at (A) trough (r=0.60, P<0.001) and (B) peak (r=0.69, P<0.0001).
5 2588 OSANAI H et al. Figure 5. Relationship between steady-state trough and peak anti-factor Xa activity (AXA) and activated partial thromboplastin time (aptt) in the overall patients. Significant but weak positive correlation was observed between AXA and aptt both at (A) trough (r=0.28, P<0.01) and (B) peak (r=0.37, P<0.001). Table 2. Significant Indicators of Trough and Peak AXA Variable β P-value Factors that raised trough AXA Dose * Female sex Age * Body weight Serum creatinine * Factors that raised peak AXA Dose <0.0001* Female sex Age * Body weight Serum creatinine * *P<0.05. AXA, anti-factor Xa activity. correlation coefficient was used. To compare parameters between groups, Mann-Whitney U-test, Wilcoxon signed-rank test, chisquared test, or Kruskal-Wallis test was used. To evaluate the factors affecting trough and peak AXA, multiple regression analysis was performed. P<0.05 was considered significant. All statistical analysis was conducted using Ekuseru-Tokei (Ekuseru-Tokei 2010, Social Survey Research Information, Tokyo, Japan). Results Patient Characteristics The characteristics of the patients whose AXA levels were evaluated are listed in Table 1. Of the patients, 76 received apixaban 5 mg b.i.d. and 48 received 2.5 mg b.i.d., including 9 patients who received 2.5 mg b.i.d. based on the decision of the attending physician, although the recommended dose was 5 mg b.i.d. The mean age, weight, serum creatinine, and creatinine clearance of these 9 patients were 76.1±4.9 years, 56.6±12.4 kg, 1.33±0.61 mg/dl, and 39.8±15.0 ml/min, respectively. AXA In the 25 patients in whom baseline, first peak, and trough AXA were measured, the respective levels were 0.01±0.02 IU/ml, 0.83±0.43 IU/ml, and 0.34±0.17 IU/ml. First trough AXA was significantly lower than steady-state trough AXA (P<0.0001), although it was significantly higher than baseline (P<0.0001). Similarly, first peak AXA was significantly lower than steadystate peak AXA (P<0.0001; Figure 1). Steady-state AXA was compared between the 3 groups according to dosage and consistency with the recommendation, namely 5 mg b.i.d. consistent with the recommendation (5-mg b.i.d. group), 2.5 mg b.i.d. consistent with the recommendation (2.5-mg b.i.d. group), and 2.5 mg b.i.d. despite a recommendation of 5 mg b.i.d. (under-dosed 2.5-mg b.i.d. group). Peak AXA was significantly higher than trough AXA in all 3 groups (Figure 2). Trough AXA did not differ significantly between the 3 groups (1.00±0.66 IU/ml, 0.84±0.47 IU/ml,
6 Anti-Factor Xa Activity on Apixaban 2589 Table 3. Patient Characteristics vs. Presence of Bleeding With bleeding Without bleeding (n=7) (n=117) P-value Age (years) 76.0± ± Male sex 5 (71.4) 57 (48.7) 0.24 Body weight (kg) 67.9± ± mg b.i.d. 4 (57.1) 72 (61.5) 0.82 Mean creatinine clearance (ml/min) 44.1± ± Mean CHADS2 score 2.7± ± Concurrent antiplatelet drugs 2 (28.6) 27 (23.1) 0.74 Trough AXA (IU/ml) 1.15± ± Peak AXA (IU/ml) 1.98± ± Data given as mean ± SD or n (%). AXA, anti-factor Xa activity. and 0.59±0.38 IU/ml, respectively; P=0.146; Figure 3A). Peak AXA was significantly higher in the 5-mg b.i.d. group than in the 2.5-mg b.i.d. group (2.05±0.73 IU/ml vs. 1.51±0.65 IU/ml, respectively; P<0.001) and the under-dosed 2.5 mg b.i.d. group (2.05±0.73 IU/ml vs. 1.23±0.46 IU/ml, respectively; P<0.01; Figure 3B). The relationship between steady-state trough and peak AXA and PT in the overall patients is shown in Figure 4. A significant and moderate positive correlation was observed between AXA and PT both at trough and at peak (r=0.60, P<0.001 and r=0.69, P<0.0001, respectively). The relationship between steady-state trough and peak AXA and aptt in the overall patients is shown in Figure 5. A significant but weak positive correlation was observed between AXA and aptt both at trough and at peak (r=0.28, P<0.01 and r=0.37, P<0.001, respectively). The results of the multiple regression analysis to evaluate the factors affecting trough and peak AXA are shown in Table 2. High dose, age, and serum creatinine were significantly related to both trough and peak AXA, but female sex and body weight were not related to either trough or peak AXA. Outcome Assessment The average follow-up period was 286±152 days, and no thromboembolism was observed. Steady-state trough and peak AXA were previously examined in 7 patients with bleeding events (Table 3). In these 7 patients, major bleeding events were observed in 2 patients, and both patients had upper gastrointestinal tract bleeding. Non-major bleeding events, including nasal bleeding, gingival bleeding, and hemosputum, were observed in 5 patients. In these 7 patients with bleeding events, trough AXA was not significantly different from that in patients without bleeding events (1.15±0.54 IU/ml vs. 0.91±0.60 IU/ml, respectively; P=0.24). Similarly, peak AXA was not significantly different between patients with and without bleeding events (1.98±0.63 IU/ml vs. 1.81±0.75 IU/ml, respectively; P=0.49). Furthermore, age, sex, body weight, dose, mean creatinine clearance, mean CHADS2 score, and concurrent antiplatelet drugs were not significantly different between patients with and without bleeding events. Discussion To the best of our knowledge, this study provides the first report of the distribution of AXA in Japanese NVAF patients on apixaban in daily clinical practice. Chromogenic AXA assay is reported to be the most appropriate method to measure the pharmacodynamics of apixaban because of the strong correla- tion with plasma apixaban concentration. 9,11 13,15,16 In this study, the relationship between AXA and PT or aptt was also evaluated, but no strong positive correlations were observed. Another advantage of chromogenic AXA assay is that it is less sensitive than PT to sample collection conditions and variations in the amount of clotting factor among patients. 12 Although chromogenic AXA assay is not yet widely available, ready-to-use liquid reagents are readily accepted, because they reduce setup time and simplify analysis. 9,11 In the present study, AXA at baseline was 0.01±0.02 IU/ml, and the absence of detectable AXA activity likely excludes the presence of physiologically important apixaban activity. AXA increased significantly from trough to peak both after first intake and in the steady state. Trough AXA at steady-state was significantly higher than both baseline and first trough AXA, probably due to the b.i.d. administration, and it achieved steady state approximately 3 days after the first dose with mild accumulation. 17,18 Frost et al reported steady-state mean trough and peak AXA in healthy subjects who received apixaban 2.5 mg twice daily (0.24 IU/ml and 1.12 IU/ml, respectively). 15 The AXA levels in that study seem to be considerably lower than the present levels, but the healthy subjects in the Frost et al study were very young, in excellent physical condition, and very different from Japanese NVAF patients. Thus, the distribution of AXA in the present study is valuable as an index for monitoring precise coagulation function on apixaban therapy in real clinical practice. In addition, the recommended dose of 5 mg b.i.d. may be reduced to 2.5 mg b.i.d. by the attending physician depending on the individual bleeding risk in real daily practice, while 2.5 mg b.i.d. is recommended strictly for patients with at least 2 of the following conditions: age 80 years, body weight 60 kg, or serum creatinine 1.5 mg/dl. It should be noted that, in the present study, however, the under-dosed 2.5-mg b.i.d. group had significantly lower peak AXA than the 5-mg b.i.d. group, even though these patients had characteristics very close to the criteria for dose reduction; thus, dose reduction against the recommendation may result in insufficient efficacy of apixaban. The 2.5-mg b.i.d. group, however, also had significantly lower peak AXA than the 5-mg b.i.d. group. Therefore, peak AXA seems to be more sensitive than trough AXA for reflecting the difference in pharmacodynamics on apixaban therapy. The relatively lower pharmacodynamics of apixaban at peak in the 2.5-mg b.i.d. group may relate to the safety profile in elderly or frail patients on apixaban therapy. 1,19 Furthermore, the present results showed that individual factors included in the dose reduction criteria have different effects on AXA. In particular, body weight was not related to either trough or peak AXA in the present study. Upreti et al
7 2590 OSANAI H et al. reported that, compared with the reference weight group (65 85 kg), AXA at 3 h after dose with 10 mg apixaban in healthy subjects was approximately 30% lower and higher in the high- ( 120 kg) and low- ( 50 kg) body weight groups, respectively. 16 They concluded that the modest change in pharmacodynamics of apixaban is unlikely to require dose adjustment for apixaban based on body weight alone. In the present study, the average body weight of the patients overall was 56.8 kg (range, kg), with small deviation and without extremely high body weight, reflecting the characteristics of Japanese NVAF patients in daily clinical practice. 3,7,20 Therefore, it is possible that body weight had limited effect on both trough and peak AXA in the present study. In contrast, given that age and serum creatinine were significantly related to both trough and peak AXA, measurement of AXA may be important to avoid excessive effects if the patient has large deviation in these factors, such as a very high age or serum creatinine. The present study had several limitations. This study was performed at a single institution with a limited number of subjects, and the observation period was relatively short. In this study, both trough and peak AXA had a tendency to be high in patients with bleeding events compared with those without events, but there was no significant difference. This may be due to the small number of bleeding events. Therefore, further research is required to ensure that monitoring of AXA can improve the efficacy and safety outcomes for patients on apixaban therapy. The peak time was defined as 3 h after drug treatment according to the previous study, 18 but the actual peak concentration may differ among individual patients. Furthermore, the different chromogenic AXA assays available on the market may have linear or exponential relationships with plasma apixaban concentration depending on the reagent, and there is interassay variability. 11 The HemosIL Liquid Heparin Kit was reported to have an exponential correlation (correlation coefficient=0.99 and coefficient of variation=0.9%), so that there may be decreased sensitivity for higher plasma concentration of apixaban. 11 Conclusions The distribution of AXA in patients with NVAF and taking apixaban in daily clinical practice was investigated, both in the acute phase and at steady state. Trough AXA was significantly higher than the baseline level. Peak AXA was significantly lower in patients taking 2.5 mg b.i.d. with or without underdose than in patients taking 5 mg b.i.d., although there were no significant differences in trough AXA between the 3 groups. Other than the dose, age and serum creatinine were significantly related to both trough and peak AXA on multiple regression analysis. In patients taking apixaban in daily clinical practice, measurement of AXA clearly showed the pharmacodynamic profile of this drug. Disclosures H.O. and M.A. have received lecture fees from Bristol-Myers Squibb, Pfizer, Bayer Yakuhin, and Boehringer Ingelheim. References 1. Granger CB, Alexander JH, McMurray JV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with nonvalvular atrial fibrillation: The ARISTOTLE-J study. Circ J 2011; 75: JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (2013): Digest version. Circ J 2014; 78: Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J 2014; 786: Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: Cuker A, Deborah M, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64: Kanemoto M, Kuhara H, Ueda T, Shinohara T, Oda T, Nakao F, et al. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation. Circ J 2014; 78: Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide. Thromb Haemost 2013; 110: Barrett Y, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban: An oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6: Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013; 76: Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: Frost C, Wang J, Nepal S, Schuster A, Barret YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2012; 75: Barco S, Cheung YW, Eikelboom JW, Coppens M. New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol 2013; 26: Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; J-ROCKET AF Study Investigators. Safety and Efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013; 77:
Stroke prevention, Clinical trials
Received: 13 May 2016 Revised: 8 August 2016 Accepted: 18 August 2016 DOI 10.1002/clc.22596 REVIEWS Special considerations for therapeutic choice of non vitamin K antagonist oral anticoagulants for Japanese
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More information2 Jean-Pierre Baeyens European Union Geriatric Medicine Society (EUGMS) representative
26 June 2014 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationEfficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score
2138 HORI M et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Arrhythmia/Electrophysiology Efficacy and Safety of Dabigatran Etexilate
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationTrue/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationDiscuss the role of idarucizumab for the management of bleeding associated with dabigatran
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationThe Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
Wood et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine (2017) 25:76 DOI 10.1186/s13049-017-0420-y ORIGINAL RESEARCH The Anticoagulated trauma patient in the age of the direct
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationSafety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients With Non-Valvular Atrial Fibrillation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Arrhythmia/Electrophysiology Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese
More informationHow does the safety and efficacy of rivaroxaban compare to that of warfarin in the prevention of stroke in non-valvular atrial fibrillation patients?
The University of Toledo The University of Toledo Digital Repository Master s and Doctoral Projects How does the safety and efficacy of rivaroxaban compare to that of warfarin in the prevention of stroke
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationDirect Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationIs Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Apixaban Effective for the Prevention
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationComparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction
Europace (2015) 17, ii69 ii75 doi:10.1093/europace/euv198 SUPPLEMENT: CLINICAL RESEARCH Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation
More informationNOACs Scegliere in Contesti Particolari
Gianluca Botto, FESC, FEHRA U.O.s. Elettrofisiologia ASST-Lariana, Como NOACs Scegliere in Contesti Particolari Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St. Jude
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationDirect oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation
J Thromb Thrombolysis (2016) 42:573 578 DOI 10.1007/s19-016-1410-z Direct oral anticoagulant use and the incidence of in the very elderly with atrial fibrillation Fatima Khan 1,2 Hans Huang 2 Yvonne H.
More informationAndreas Clemens 1,2 *, Herbert Noack 3, Martina Brueckmann 3,4, Gregory Y. H. Lip 5. Abstract. Introduction
Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria Andreas Clemens 1,2 *, Herbert Noack 3, Martina
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAcute Thrombocytopenia after Initiating Anticoagulation with Rivaroxaban
CASE REPORT Acute Thrombocytopenia after Initiating Anticoagulation with Rivaroxaban Yohei Mima 1, Yuhei Sangatsuda 2, Masahiro Yasaka 1, Yoshiyuki Wakugawa 1, Shinji Nagata 2 and Yasushi Okada 1 Abstract
More informationEvaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System : In Vitro and Ex Vivo Studies
Elmer ress Original Article J Clin Med Res. 2016;8(12):899-907 Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System : In Vitro and Ex
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationAbstract. Introduction. imedpub Journals Doson Chua* Research Article. Cardiovascular Investigations: Open Access
Research Article imedpub Journals www.imedpub.com Cardiovascular Investigations: Open Access Vol. 2 No.1: 1 Use of Non-vitamin K Antagonist Oral Anticoagulants (NOAC) for Stroke Prevention in Patients
More informationCOAGULATION TESTING AND NEW ORAL ANTICOAGULANTS
COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS SOPHIE TESTA Haemostasis and Thrombosis Center ASST-Cremona, Italy ANTICOAGULANT DRUGS Eikelboom JW, Weitz JI. Circulation 2010;6:1523-32 DRUGS UH LAB aptt
More informationlaboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie.
laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. Disclosures Malake Naboulsi declare to meeting attendees that
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationNon Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation Meta-Analysis
Non Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation Meta-Analysis Kang-Ling Wang, MD; Gregory Y.H. Lip, MD; Shing-Jong Lin, MD, PhD;
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationLaboratory Monitoring Measurement of the DOACs
1 Laboratory Monitoring Measurement of the DOACs ACC Anticoagulation Consortium Roundtable Meeting October 24, 2015 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures
More informationEligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation Comparison Between Patients With Versus Without Stroke
Eligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation Comparison Between Patients With Versus Without Stroke Chang Hyo Yoon, MD; Yoon Kyung Park, MD; Suk Jae Kim, MD;
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationBleeding Complications in Patients Receiving Direct Oral Anticoagulant Therapy in the Post Clinical Trial General Practice
American Journal of Clinical and Experimental Medicine 2017; 5(3): 64-68 http://www.sciencepublishinggroup.com/j/ajcem doi: 10.11648/j.ajcem.20170503.12 ISSN: 2330-8125 (Print); ISSN: 2330-8133 (Online)
More informationDepartment of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea h
Journal of Stroke 2015;17(2):210-215 http://dx.doi.org/10.5853/jos.2015.17.2.210 Guideline Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationDavid Stultz, MD, FACC July 24, Handout available at
David Stultz, MD, FACC July 24, 2012 Handout available at www.drstultz.com Unfortunately, no conflicts of interest Brand names will be used On label and Off label use will be discussed Unapproved investigational
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationRenal Function Considerations for Stroke Prevention in Atrial Fibrillation
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation Wednesday, March 28, 2018, 1:00PM ET Presenters: John Fanikos, RPh, MBA Curt Mahan, PharmD Paul Dobesh, PharmD, FCCP, BCPS Presenters
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationPRACTICAL ISSUES OF ANTICOAGULANT ACCEPTANCE IN AVIATION MEDICINE
87 th ASMA ANNUAL SCIENTIFIC MEETING ATLANTIC CITY - April 24-28, 2016 PRACTICAL ISSUES OF ANTICOAGULANT ACCEPTANCE IN AVIATION MEDICINE S. BISCONTE (1), A. HORNEZ (2), J. MONIN (2), D. DUBOURDIEU (2),
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationEfficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
New Technologies, Diagnostic Tools and Drugs 981 Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation An indirect comparison
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationConflict of interest statement
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis
More informationOrgan-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
918 Theme Issue Article Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials Thomas Vanassche; Jack Hirsh; John W. Eikelboom; Jeffrey S. Ginsberg Population Health Research
More information